Postoperative Pain Control With Lipossomic Extended Release Bupivacaine
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03560362 |
|
Recruitment Status : Unknown
Verified June 2018 by Benny Weksler, University of Tennessee Health Science Center.
Recruitment status was: Recruiting
First Posted : June 18, 2018
Last Update Posted : June 20, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Pain, Postoperative Lung Cancer | Drug: Bupivacaine liposome Drug: Bupivacaine / Epinephrine | Phase 1 Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 50 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Randomized Trial Comparing Bupivacaine vs Lipossomic Extended Release Bupivacaine for Postoperative Pain Control After Minimally Invasive Thoracic Surgery |
| Actual Study Start Date : | July 9, 2015 |
| Estimated Primary Completion Date : | October 31, 2018 |
| Estimated Study Completion Date : | October 31, 2018 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Bupivacaine with epinephrine
Patients will receive intraoperative intercostal nerve block with bupivacaine
|
Drug: Bupivacaine / Epinephrine |
|
Experimental: Lipossomal extended release bupivacaine
Patients will receive intraoperative intercostal nerve block with lipossomal extended release bupivacaine
|
Drug: Bupivacaine liposome |
- Postoperative pain [ Time Frame: 3-5 days post op ]Pain assessment with Visual Analog Scale (VAS). This is a numeric pain scale widely used in healthcare that ranks pain from 0 (no pain) to 10 (unbearable pain). A pain score below 3 is considered good.
- Postoperative complications [ Time Frame: 90 days post op ]Any complication occuring in the first 90 days classified according to the Clavien-Dindo classification.
- Narcotic used [ Time Frame: 3-5 days post op ]Amount of morphine equivalent dosage used in the postoperative period
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria: Patients who will be undergoing minimally invasive thoracic surgery
- Patients who will be undergoing minimally invasive thoracic surgery
Exclusion Criteria:
- Open surgery
- Chronic use of narcotics
- Use of pregabalin or similar
- Significant liver or kidney dysfunction
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03560362
| Contact: Benny Weksler, MD | 901-448-2918 | bweksler@uthsc.edu | |
| Contact: Suzie Glass, RN | 901-448-2918 | Suzie.Glass@mlh.org |
| United States, Tennessee | |
| Methodist University Hospital | Recruiting |
| Memphis, Tennessee, United States, 38104 | |
| Contact: Benny Weksler 901-448-2918 bweksler@uthsc.edu | |
| Principal Investigator: | Benny Weksler, MD | University of Tennessee Health Science Center |
| Responsible Party: | Benny Weksler, Professor of Surgery, University of Tennessee Health Science Center |
| ClinicalTrials.gov Identifier: | NCT03560362 |
| Other Study ID Numbers: |
15-03838 |
| First Posted: | June 18, 2018 Key Record Dates |
| Last Update Posted: | June 20, 2018 |
| Last Verified: | June 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
bupivacaine lipossomal extended release bupivacaine Intercostal nerve block thoracic surgery minimally invasive surgery |
|
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Neurologic Manifestations Epinephrine Bupivacaine Anesthetics, Local Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents |
Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic beta-Agonists Bronchodilator Agents Autonomic Agents Anti-Asthmatic Agents Respiratory System Agents Mydriatics Sympathomimetics Vasoconstrictor Agents |

